TrialBlood advances2022

Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome.

Aaron T Gerds et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.